Galapagos NV [GLPGA] vs Vivoryon [VVY] Detailed Stock Comparison

Galapagos NV

EURONEXT
Loading...

Vivoryon Therapeutics N.V.

EURONEXT
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Galapagos NV wins in 12 metrics, Vivoryon Therapeutics N.V. wins in 3 metrics, with 0 ties. Galapagos NV appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Galapagos NV Vivoryon Therapeutics N.V. Better
P/E Ratio (TTM) 5.10 -1.58 Galapagos NV
Price-to-Book Ratio 0.50 11.07 Galapagos NV
Debt-to-Equity Ratio 0.21 2.26 Galapagos NV
PEG Ratio -6.32 -3.27 Vivoryon Therapeutics N.V.
EV/EBITDA -2.39 -2.41 Galapagos NV
Profit Margin (TTM) 28.85% 0.00% Galapagos NV
Operating Margin (TTM) 88.00% 0.00% Galapagos NV
EBITDA Margin (TTM) 88.00% N/A N/A
Return on Equity 10.42% -145.47% Galapagos NV
Return on Assets (TTM) 8.87% -67.68% Galapagos NV
Free Cash Flow (TTM) $-271.32M $-8.46M Vivoryon Therapeutics N.V.
1-Year Return -1.66% -29.88% Galapagos NV
Price-to-Sales Ratio (TTM) 1.46 N/A N/A
Enterprise Value $-1.36B $30.39M Vivoryon Therapeutics N.V.
EV/Revenue Ratio -1.22 N/A N/A
Gross Profit Margin (TTM) 99.95% N/A N/A
Revenue per Share (TTM) $17 $0 Galapagos NV
Earnings per Share (Diluted) $4.85 $-0.48 Galapagos NV
Beta (Stock Volatility) 0.15 1.44 Galapagos NV

Galapagos NV vs Vivoryon Therapeutics N.V. Stock Performance Analysis

Loading Price Chart...

GLPGA
VVY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Galapagos NV0.00%1.96%6.58%-12.43%-6.24%-11.43%
Vivoryon Therapeutics N.V.-0.43%-8.06%-8.80%-16.79%-24.50%-21.38%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Galapagos NV-1.66%-35.89%-60.48%-44.69%414.23%177.11%
Vivoryon Therapeutics N.V.-29.88%-91.69%-93.20%-93.99%-94.14%-94.14%

Performance & Financial Health Analysis: Galapagos NV vs Vivoryon Therapeutics N.V.

MetricGLPGAVVY
Market Information
Market Cap i€1.63B€37.02M
Market Cap CategoryLarge capSmall cap
10 Day Avg. Volume i57,55319,087
90 Day Avg. Volume i88,73429,797
Last Close€24.94€1.14
52 Week Range€22.62 - €32.74€1.10 - €1.84
% from 52W High-23.82%-37.77%
All-Time High€252.90 (Feb 17, 2020)€27.19 (Jan 11, 2016)
% from All-Time High-90.14%-95.81%
Growth Metrics
Quarterly Revenue Growth10.93%N/A
Quarterly Earnings Growth29.91%N/A
Financial Health
Profit Margin (TTM) i0.29%0.00%
Operating Margin (TTM) i0.88%0.00%
Return on Equity (TTM) i0.10%-1.45%
Debt to Equity (MRQ) i0.212.26
Cash & Liquidity
Book Value per Share (MRQ)€49.11€0.12
Cash per Share (MRQ)€45.50€0.18
Operating Cash Flow (TTM) i€-257,456,000€-10,370,000
Levered Free Cash Flow (TTM) i€344.64M€-6,199,875
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Galapagos NV vs Vivoryon Therapeutics N.V.

MetricGLPGA (Apr 24, 2026)VVY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i5.10-1.58
Forward P/E i-6.32-3.27
PEG Ratio i-6.32-3.27
Price to Sales (TTM) i1.46N/A
Price to Book (MRQ) i0.5011.07
Market Capitalization
Market Capitalization i€1.63B€37.02M
Enterprise Value i€-1,355,567,744€30.39M
Enterprise Value Metrics
Enterprise to Revenue i-1.22N/A
Enterprise to EBITDA i-2.39-2.41
Risk & Other Metrics
Beta i0.151.44
Book Value per Share (MRQ) i€49.11€0.12

Financial Statements Comparison: Galapagos NV vs Vivoryon Therapeutics N.V.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLPGA (2025)VVY (2025)
Revenue/Sales i1.11B0
Cost of Goods Sold i29.74MN/A
COGS % of Revenue i2.7%-
Gross Profit i1.08BN/A
Gross Margin i97.3%-
Research & Development i459.42M4.38M
Operating Income (EBIT) i501.39M-8.91M
Operating Margin i45.1%-
EBITDA i604.67M-8.66M
EBITDA Margin i54.4%-
Pre-Tax Income i300.87M-8.85M
Pre-Tax Income % of Revenue i27.1%-
Income Tax i-18.62M0
Income Tax % of Revenue i-1.7%-
Net Income (Profit) i320.88M-8.85M
Profit Margin i28.9%-

Balance Sheet & Liquidity Metrics

MetricGLPGA (2025)VVY (2025)
Cash & Equivalents i87.87M5.62M
Total Current Assets i3.08B6.43M
Total Current Assets % of Revenue i276.9%-
Total Current Liabilities i152.86M837,000
Total Current Liabilities % of Revenue i13.7%-
Long-Term Debt i5.19M44,000
Long-Term Debt % of Revenue i0.5%-
Total Shareholders Equity i3.24B4.73M
Retained Earnings i210.58M-178.22M
Retained Earnings % of Revenue i18.9%-
Property, Plant & Equipment i3.18M121,000

Cash Flow Statement Comparison

MetricGLPGA (2025)VVY (2025)
Operating Cash Flow i-594.79M-8.11M
Operating Cash Flow % of Revenue i-53.5%-
Capital Expenditures i-13.24M-6,000
Free Cash Flow i-271.32M-8.46M
FCF Margin i-24.4%-
Debt Repayment i-3.27MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLPGAVVY
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i65.90M26.07M
Float Shares i44.54M22.38M
% Held by Insiders i25.36%21.46%
% Held by Institutions i32.49%8.90%
% Held by Public i42.15%69.64%

Dividend Analysis & Yield Comparison: Galapagos NV vs Vivoryon Therapeutics N.V.

MetricGLPGAVVY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A